Fusion Pharmaceuticals (FUSN) Stock Forecast, Price Target & Predictions
FUSN Stock Forecast
Fusion Pharmaceuticals stock forecast is as follows: an average price target of $15.25 (represents a -29.23% downside from FUSN’s last price of $21.55) and a rating consensus of 'Hold', based on 11 wall street analysts offering a 1-year stock forecast.
FUSN Price Target
The average price target for Fusion Pharmaceuticals (FUSN) is $15.25 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $6.00. This represents a potential -29.23% downside from FUSN's last price of $21.55.
FUSN Analyst Ratings
According to 11 Wall Street analysts, Fusion Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for FUSN stock is 2 'Strong Buy' (18.18%), 2 'Buy' (18.18%), 6 'Hold' (54.55%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Fusion Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 19, 2024 | Matthew Harrison | Morgan Stanley | $21.00 | $21.18 | -0.85% | -2.55% |
| Mar 19, 2024 | Suji Jeong | Jefferies | $21.00 | $21.18 | -0.85% | -2.55% |
| Sep 29, 2023 | Jeff Jones | Oppenheimer | $13.00 | $2.60 | 400.00% | -39.68% |
| Nov 30, 2022 | - | Leerink Partners | $6.00 | $2.16 | 177.78% | -72.16% |
The latest Fusion Pharmaceuticals stock forecast, released on Mar 19, 2024 by Matthew Harrison from Morgan Stanley, set a price target of $21.00, which represents a -0.85% decrease from the stock price at the time of the forecast ($21.18), and a -2.55% decrease from FUSN last price ($21.55).
Fusion Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $21.00 |
| Last Closing Price | $21.55 | $21.55 | $21.55 |
| Upside/Downside | -100.00% | -100.00% | -2.55% |
In the current month, the average price target of Fusion Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fusion Pharmaceuticals's last price of $21.55. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 16, 2024 | Cowen & Co. | - | Hold | Downgrade |
| Mar 20, 2024 | Wedbush | Sector Perform | Sector Perform | Hold |
| Mar 19, 2024 | Leerink Partners | - | Market Perform | Downgrade |
| Mar 04, 2024 | Wedbush | Strong Buy | Strong Buy | Hold |
| Jan 26, 2024 | Wedbush | Strong Buy | Strong Buy | Hold |
| Dec 27, 2023 | Raymond James | Outperform | Strong Buy | Upgrade |
| Dec 27, 2023 | RBC Capital | Strong Buy | Strong Buy | Hold |
| Jun 23, 2023 | B. Riley Securities | - | Neutral | Initialise |
| Jun 23, 2023 | Compass Point | - | Sell | Initialise |
| Jun 23, 2023 | Piper Sandler | - | Neutral | Initialise |
Fusion Pharmaceuticals's last stock rating was published by Cowen & Co. on Apr 16, 2024. The company Downgrade its FUSN rating from "null" to "Hold".
Fusion Pharmaceuticals Financial Forecast
Fusion Pharmaceuticals Revenue Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $28.00K | $140.00K | - | - | $585.00K | - | - |
| Avg Forecast | $1.79M | $597.70K | - | - | - | - | - | - | - | - | - | - | $193.50K | $186.00K | $192.67K | $168.50K | $412.40K | $86.00K | $75.00K | $8.57M | $17.00K | $100.00K | $137.50K | $1.42M | $260.50K | $3.33M |
| High Forecast | $1.79M | $597.70K | - | - | - | - | - | - | - | - | - | - | $193.50K | $186.00K | $192.67K | $168.75K | $793.08K | $86.00K | $75.00K | $8.57M | $17.00K | $100.00K | $137.50K | $1.42M | $260.50K | $3.33M |
| Low Forecast | $1.79M | $597.70K | - | - | - | - | - | - | - | - | - | - | $193.50K | $186.00K | $192.67K | $168.25K | $31.72K | $86.00K | $75.00K | $8.57M | $17.00K | $100.00K | $137.50K | $1.42M | $260.50K | $3.33M |
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 8.24% | - | - | 0.41% | - | - |
Fusion Pharmaceuticals's average Quarter revenue forecast for Jul 23 based on 4 analysts is $75.00K, with a low forecast of $75.00K, and a high forecast of $75.00K. FUSN's average Quarter revenue forecast represents a 167.86% increase compared to the company's last Quarter revenue of $28.00K (Mar 23).
Fusion Pharmaceuticals EBITDA Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-27.91M | - | - | $-23.08M | $-23.79M | - | - | $-20.32M | - | - |
| Avg Forecast | $-358.62K | $-119.54K | - | - | - | - | - | - | - | - | - | - | $-38.70K | $-37.20K | $-38.53K | $-33.70K | $-82.48K | $-17.20K | $-15.00K | $-1.71M | $-3.40K | $-20.00K | $-27.50K | $-20.50M | $-52.10K | $-666.67K |
| High Forecast | $-358.62K | $-119.54K | - | - | - | - | - | - | - | - | - | - | $-38.70K | $-37.20K | $-38.53K | $-33.65K | $-6.34K | $-17.20K | $-15.00K | $-1.71M | $-3.40K | $-20.00K | $-27.50K | $-16.40M | $-52.10K | $-666.67K |
| Low Forecast | $-358.62K | $-119.54K | - | - | - | - | - | - | - | - | - | - | $-38.70K | $-37.20K | $-38.53K | $-33.75K | $-158.62K | $-17.20K | $-15.00K | $-1.71M | $-3.40K | $-20.00K | $-27.50K | $-24.60M | $-52.10K | $-666.67K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 338.44% | - | - | 13.46% | 6998.53% | - | - | 0.99% | - | - |
undefined analysts predict FUSN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fusion Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Fusion Pharmaceuticals Net Income Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-28.18M | - | - | $-24.29M | $-24.62M | - | - | $-19.91M | - | - |
| Avg Forecast | $-47.38M | $-45.85M | $-41.29M | $-36.24M | $-35.86M | $-35.30M | $-34.74M | $-34.94M | $-37.41M | $-36.70M | $-34.72M | $-34.33M | $-30.26M | $-30.28M | $-29.53M | $-31.11M | $-28.40M | $-33.52M | $-32.92M | $-25.96M | $-45.94M | $-41.99M | $-43.40M | $-20.74M | $-48.42M | $-15.50M |
| High Forecast | $-47.38M | $-45.85M | $-41.29M | $-36.24M | $-35.86M | $-35.30M | $-34.74M | $-34.94M | $-37.41M | $-36.70M | $-34.72M | $-34.33M | $-30.26M | $-30.28M | $-22.35M | $-31.11M | $-22.56M | $-33.52M | $-32.92M | $-25.96M | $-45.94M | $-41.99M | $-43.40M | $-16.59M | $-48.42M | $-15.50M |
| Low Forecast | $-47.38M | $-45.85M | $-41.29M | $-36.24M | $-35.86M | $-35.30M | $-34.74M | $-34.94M | $-37.41M | $-36.70M | $-34.72M | $-34.33M | $-30.26M | $-30.28M | $-35.12M | $-31.11M | $-35.09M | $-33.52M | $-32.92M | $-25.96M | $-45.94M | $-41.99M | $-43.40M | $-24.89M | $-48.42M | $-15.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | - | - | 0.94% | 0.54% | - | - | 0.96% | - | - |
Fusion Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FUSN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Fusion Pharmaceuticals SG&A Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.63M | - | - | $9.01M | $6.95M | - | - | $8.45M | - | - |
| Avg Forecast | $20.39M | $6.80M | - | - | - | - | - | - | - | - | - | - | $2.20M | $2.11M | $2.19M | $1.92M | $4.69M | $977.79K | $852.72K | $97.45M | $193.28K | $1.14M | $1.56M | $16.12M | $2.96M | $37.90M |
| High Forecast | $20.39M | $6.80M | - | - | - | - | - | - | - | - | - | - | $2.20M | $2.11M | $2.19M | $1.92M | $9.02M | $977.79K | $852.72K | $97.45M | $193.28K | $1.14M | $1.56M | $16.12M | $2.96M | $37.90M |
| Low Forecast | $20.39M | $6.80M | - | - | - | - | - | - | - | - | - | - | $2.20M | $2.11M | $2.19M | $1.91M | $360.68K | $977.79K | $852.72K | $97.45M | $193.28K | $1.14M | $1.56M | $16.12M | $2.96M | $37.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.63% | - | - | 0.09% | 35.96% | - | - | 0.52% | - | - |
Fusion Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $1.92M, based on 3 Wall Street analysts, with a range of $1.91M to $1.92M. The forecast indicates a -74.88% fall compared to FUSN last annual SG&A of $7.63M (Dec 23).
Fusion Pharmaceuticals EPS Forecast
| Dec 27 | Oct 27 | Jul 27 | Mar 27 | Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Oct 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | 3 | 6 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 3 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.39 | - | - | $-0.45 | $-0.55 | - | - | $-0.46 | - | $-0.32 |
| Avg Forecast | $-0.57 | $-0.55 | $-0.49 | $-0.43 | $-0.43 | $-0.42 | $-0.41 | $-0.42 | $-0.45 | $-0.44 | $-0.41 | $-0.41 | $-0.36 | $-0.36 | $-0.35 | $-0.37 | $-0.34 | $-0.40 | $-0.39 | $-0.31 | $-0.55 | $-0.50 | $-0.52 | $-0.44 | $-0.58 | $-0.18 |
| High Forecast | $-0.57 | $-0.55 | $-0.49 | $-0.43 | $-0.43 | $-0.42 | $-0.41 | $-0.42 | $-0.45 | $-0.44 | $-0.41 | $-0.41 | $-0.36 | $-0.36 | $-0.27 | $-0.37 | $-0.27 | $-0.40 | $-0.39 | $-0.31 | $-0.55 | $-0.50 | $-0.52 | $-0.44 | $-0.58 | $-0.18 |
| Low Forecast | $-0.57 | $-0.55 | $-0.49 | $-0.43 | $-0.43 | $-0.42 | $-0.41 | $-0.42 | $-0.45 | $-0.44 | $-0.41 | $-0.41 | $-0.36 | $-0.36 | $-0.42 | $-0.37 | $-0.42 | $-0.40 | $-0.39 | $-0.31 | $-0.55 | $-0.50 | $-0.52 | $-0.44 | $-0.58 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | - | - | 1.45% | 1.00% | - | - | 1.04% | - | 1.73% |
According to undefined Wall Street analysts, Fusion Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FUSN previous annual EPS of $NaN (undefined).
Fusion Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RAPT | RAPT Therapeutics | $2.72 | $42.20 | 1451.47% | Hold |
| PMVP | PMV Pharmaceuticals | $1.66 | $24.75 | 1390.96% | Buy |
| CHRS | Coherus BioSciences | $0.72 | $9.00 | 1150.00% | Hold |
| PASG | Passage Bio | $0.65 | $6.00 | 823.08% | Buy |
| SPRO | Spero Therapeutics | $1.31 | $10.00 | 663.36% | Buy |
| FENC | Fennec Pharmaceuticals | $4.95 | $15.75 | 218.18% | Buy |
| BCAB | BioAtla | $2.06 | $5.00 | 142.72% | Buy |
| BCYC | Bicycle Therapeutics | $23.64 | $54.40 | 130.12% | Buy |
| OLMA | Olema Pharmaceuticals | $12.52 | $28.50 | 127.64% | Buy |
| NAMS | NewAmsterdam Pharma Company | $21.78 | $36.50 | 67.58% | Buy |
| RLMD | Relmada Therapeutics | $3.40 | $5.67 | 66.76% | Buy |
| KROS | Keros Therapeutics | $66.45 | $102.60 | 54.40% | Buy |
| BOLT | Bolt Biotherapeutics | $0.65 | $1.00 | 53.85% | Hold |
| HRMY | Harmony Biosciences | $34.29 | $48.86 | 42.49% | Buy |
| EWTX | Edgewise Therapeutics | $36.62 | $45.00 | 22.88% | Buy |
| JANX | Janux Therapeutics | $54.89 | $61.20 | 11.50% | Buy |
| IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
| FUSN | Fusion Pharmaceuticals | $21.55 | $15.25 | -29.23% | Hold |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
FUSN Forecast FAQ
Is Fusion Pharmaceuticals a good buy?
No, according to 11 Wall Street analysts, Fusion Pharmaceuticals (FUSN) is considered a 'Hold'. The rating consensus is based on 2 'Strong Buy' and 2 'Buy' recommendations, accounting for 36.36% of FUSN's total ratings.
What is FUSN's price target?
Fusion Pharmaceuticals (FUSN) average price target is $15.25 with a range of $6 to $21, implying a -29.23% from its last price of $21.55. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Fusion Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for FUSN stock, the company can go down by -29.23% (from the last price of $21.55 to the average price target of $15.25), down by -2.55% based on the highest stock price target, and down by -72.16% based on the lowest stock price target.
Can Fusion Pharmaceuticals stock reach $30?
FUSN's average twelve months analyst stock price target of $15.25 does not support the claim that Fusion Pharmaceuticals can reach $30 in the near future.
What are Fusion Pharmaceuticals's analysts' financial forecasts?
Fusion Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-141M (high $-141M, low $-141M), average SG&A $0 (high $0, low $0), and average EPS is $-1.681 (high $-1.681, low $-1.681). FUSN's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $2.39M (high $2.39M, low $2.39M), average EBITDA is $-478K (high $-478K, low $-478K), average net income is $-171M (high $-171M, low $-171M), average SG&A $27.18M (high $27.18M, low $27.18M), and average EPS is $-2.038 (high $-2.038, low $-2.038).
Did the FUSN's actual financial results beat the analysts' financial forecasts?
Based on Fusion Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $2.07M, which missed the average analysts forecast of $9.14M by -77.39%. Apple's EBITDA was $-99.232M, beating the average prediction of $-1.829M by 5325.59%. The company's net income was $-94.897M, missing the average estimation of $-121M by -21.45%. Apple's SG&A was $31.2M, missing the average forecast of $103.97M by -70.00%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-1.442 by -99.90%. In terms of the last quarterly report (Mar 2023), Fusion Pharmaceuticals's revenue was $28K, missing the average analysts' forecast of $8.57M by -99.67%. The company's EBITDA was $-23.079M, beating the average prediction of $-1.714M by 1246.28%. Fusion Pharmaceuticals's net income was $-24.291M, missing the average estimation of $-25.963M by -6.44%. The company's SG&A was $9.01M, missing the average forecast of $97.45M by -90.76%. Lastly, the company's EPS was $-0.45, beating the average prediction of $-0.31 by 45.20%